N=55 pregnancies | TLD | PTLD* | PTLD† | FD‡ | FD§ | EPL |
>37.0 weeks | 34.0–36.6 weeks | <34.0 weeks | >20.0 weeks | 10.0–19.6 weeks | <10.0 weeks | |
n: 26 | n:4 | n:5 | n:2 | n:3 | n:15 | |
47% | 7% | 9% | 4% | 5% | 27% | |
Additional pregnancy morbidity | ||||||
SGA and PEC | NR | 1** | NR | NR | NR | NR |
SGA | 1 | NR | 1‡‡ | NR | NR | NR |
PEC | NR | 2†† | 2§§ | NR | NR | NR |
PI | NR | NR | NR | NR | NR | NR |
History of SLE¶¶ | 6 (23%) | 2 (50%) | 1 (20%) | 1 (50%) | 1 (33%) | 3 (20%) |
History of thrombosis | 13 (50%) | 2 (50%) | 5 (100%) | 1 (50%) | 1 (33%) | 10 (67%) |
Arterial | 5 (19%) | – | 1 (20%) | – | – | 1 (7%) |
Venous | 10 (38%) | 2 | 4 (80%) | 1 (50%) | 1 (33%) | 10 (67%) |
Arterial and venous | 2 (8%) | – | – | – | – | 1 (7%) |
History of pregnancy | 21 (81%) | 1 (25%) | 4 (80%) | – | 1 (33%) | 11 (73%) |
History of pregnancy morbidity | 15 (58%) | 1 (25%) | 4 (80%) | – | 1 (33%) | 9 (60%) |
≥1 fetal death >10 weeks | 10 (38%) | – | 2 (40%) | – | – | 6 (40%) |
≥1 preterm delivery <34 weeks | 4 (15%) | – | – | – | – | 4 (27%) |
≥1 (pre)-embryonic loss <10 weeks | 7 (27%) | – | 2 (40%) | – | – | 5 (33%) |
Laboratory category | ||||||
LA (+) only¶ | 9 (35%) | 2 (50%) | 2 (40%) | 1 (50%) | 1 (33%) | 2 (13%) |
Double aPL (+) | 6 (23%) | – | 1 (20%) | 1 (50%) | 2 (67%) | 7 (47%) |
Triple aPL (+) | 9 (35%) | 2 (50%) | 2 (40%) | – | – | 5 (33%) |
Treatment during pregnancy | ||||||
No LDA/LMWH | – | – | – | – | 1 (33%) | 6 (40%) |
LDA alone | 2 (8%) | – | – | – | 1 (33%) | 2 (13%) |
LMWH alone | 5 (19%) | – | – | – | 1 (33%) | – |
LDA+LMWH | 19 (73%) | 4 (100%) | 5 (100%) | 2 (100%) | – | 7 (47%) |
Hydroxychloroquine | 17 (65%) | 2 (50%) | 2 (40%) | – | 1 (33%) | 5 (33%) |
Hypertension | 1 (4%) | – | – | – | – | 1 (7%) |
Obesity | 4 (15%) | – | 3 (60%) | – | – | 3 (20%) |
*One spontaneous PTLD, GA 34 weeks.
†Two spontaneous PTLD, GA 32 weeks and 33 weeks respectively.
‡Two fetal deaths associated with anomalies: 1 triple X syndrome (47 XXX) at 21 weeks, 1 cystic fibrosis at 20 weeks.
§1/3 morphologically normal, 2/3 fetal loss of unknown fetal status.
¶aCL and aβ2GPI not tested in two pregnancies; aβ2GPI not tested in three pregnancies.
**GA at 36 weeks.
††GA 35 weeks and 36.4 weeks.
‡‡GA 24 weeks.
§§GA 33.6 weeks and 26 weeks.
¶¶pregnancy outcomes in 14 patients with SLE were 6 for TLD (1 SGA), 3 PTLD ((2 PEC at GA 36.4 weeks and 26 weeks), 2 FD (GA 20 weeks and 12 weeks), and 3 EPL.
aCL, anticardiolipin antibody; aβ2GPI, anti-β2 glycoprotein-I; EPL, early pregnancy loss; FD, fetal death; GA, gestational age; LA, lupus anticoagulant; LDA, low-dose aspirin; LMWH, low-molecular-weight heparin; NR, not reported; PEC, pre-eclampsia; PI, placental insufficiency; PTLD, preterm live delivery; SGA, small-for-gestational age; TLD, term live delivery.